By David C. Holzman
Two studies demonstrate efficacy and safety of a new drug, cefiderocol (Fetroja, Shionogi), against some of the most difficult-to-treat gram-negative bacterial infections (Lancet 2020 Oct 12. [Epub ahead of print]).
Both studies were phase 3 multicenter trials that took place in 16 and 17 countries, initially including almost 400 patients combined.
The larger APEKS-NP trial compared the efficacy and safety of cefiderocol against best available therapy (BAT), in this case